What the evidence actually suggests The strongest clinical evidence supports the idea that GLP-1 medications can improve inflammatory markers in many patients, particularly those with obesity, type 2 diabetes, fatty liver disease, and cardiovascular risk
Michael Calore is @snackfight
When the medications reach the brain and bind to receptors in the habenula, they reduce the compulsive pull behind behaviors like overeating often described by patients as "food noise." That's one reason why GLP-1s are now being studied as potential tools for treating or preventing substance use disorders
Esse processo facilita a liplise (queima de gordura para obteno de energia), sendo til para quem segue uma dieta para perda de peso ou ganho de massa muscular
Digestive conditions like Crohns disease, celiac disease, and chronic gastritis, along with medications such as metformin or acid reflux drugs, can further reduce absorption